Data presented at the North American Cystic Fibrosis Conference by Transave shows "improved lung function with significant reduction in bacterial density" for CF patients treated with Arikace liposomal amikacin for inhalation. An affiliate of the Cystic Fibrosis Foundation provided almost $4 million for the development of Arikace. The inhalation solution is delivered using Pari’s eFlow nebulizer. Read the company’s press release.
